After an interim review , the trial 's placebo group was discontinued and thereafter the active groups were continued , and participants initially randomly assigned to placebo were offered rerandomisation in a 1:1 ratio to tenofovir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate as PrEP .